Glioblastoma Survival with Partial Gains and Losses in Chromosomes 7 and 10 at Henry Ford Health
Recommended Citation
Klonoski J, Fang X, Shaw B, Tabbarah AZ, Wen T. Glioblastoma Survival with Partial Gains and Losses in Chromosomes 7 and 10 at Henry Ford Health. J Neuropathol Exp Neurol 2026; 85(6):611-612.
Document Type
Conference Proceeding
Publication Date
5-21-2026
Publication Title
J Neuropathol Exp Neurol
Keywords
Neurosciences & Neurology, Pathology
Abstract
Background: The gain of chromosome 7 and the loss of chromosome 10 are one of the essential diagnostic criteria for the diagnosis of IDH-wildtype glioblastomas in patients above the age of 40. Combinations including partial gain of chromosome 7 and/or partial loss of chromosome 10 are less investigated. The largest study to date included 33 cases of nine possible combinations of chromosome 7 gains and chromosome 10 losses. From this work it was surmised that only the gain of 7q along with whole chromosome 10 loss or the loss of 10q along with gain of whole chromosome 7 portend to carry the prognostic significance of the 7/10 signature. Methods: At Henry Ford Health we used Oncoscan chromosomal microarrays to identify partial 7 gains and 10 losses along with NGS to better characterize the tumors. Results: We identified 22 cases within the previously established groups of 7q+/10 − (n = 6), 7+/10q − (n = 3), 7q+/10q − (n = 2), 7p+/10 − (n = 5), 7+/10p − (n = 3) and 7p+/10q − (n = 3). No cases with either 7q+/10p- or 7p+/10p-. Most cases possess a TERT promoter mutation (19/22) and EGFR amplification/gain (20/22), however, they differ in other variants such as homozygous CDKN2A deletions (15/22) and TP53 mutations (10/22). Survival data is currently available for only 13 cases and statistical analysis shows no significant differences in time of survival or histologic features but an expected trend in longer survival with 7p+/10- and 7+/10p-. Conclusions: Our work adds three cases to the previously uncharacterized 7p+/10q- group and two cases to the minimally represented 7+/10p- group. It may also point to a fundamental requirement for 7q gain or 10q loss in that neither cohort contains glioblastomas with 7p+/10p-. This work serves to address a critical issue in diagnostic neuropathology and points toward a need for more data in order to determine prognosis and possibly optimize treatment for glioblastoma.
Volume
85
Issue
6
First Page
611
Last Page
612
